Session: SAT 554-583-Male Reproductive Endocrinology & Case Reports
Poster Board SAT-578
Methods: RHYME is a multi-center registry of 999 men with clinically-diagnosed HG (naïve to androgen treatment) from 25 sites in 6 European countries (DE/ES/IT/NL/SE/UK). T was measured in a central laboratory by liquid chromatography-tandem mass spectrometry. Cardiometabolic factors included measured height and weight [used to calculate body mass index (BMI)], waist, and blood pressure [high blood pressure (HBP) defined as SBP≥140 or DBP≥90mmHg]. Hypercholesterolemia, diabetes, and use of anti-hypertensive, lipid-lowering, and anti-diabetic medications were assessed by medical record. Smoking and physical activity were assessed by self-reported questionnaire. Unadjusted associations with T were assessed via Pearson’s correlation coefficient (r) for continuous variables and t-tests for binary categorical variables. Differences in geometric mean T (log-scale) in relation to cardiometabolic factors were assessed via multivariable linear regression models controlling for age, BMI, HG duration, smoking, PA, self-rated health, number of comorbidities, blood draw time, and country.
Results: Mean age and T were 59±10.5y and 9.5±1.6nmol/L, with high rates of obesity (44%), HBP (50%), hypercholesterolemia (31%), and diabetes (29%). There were significant differences in T by country (range: UK, 9.9nmol/L; DE, 11.8nmol/L). T levels were significantly correlated with BMI (r=-0.23) and waist (r=-0.20) but not SBP or DBP. Mean T levels were unrelated to smoking, physical activity, HBP, hypercholesterolemia, diabetes, or use of medications to treat these conditions in unadjusted or adjusted analyses. More men with lower T were taking anti-hypertensives and lipid-lowering agents, but the relation between T and HBP or hypercholesterolemia was not different in men taking or not taking these medications. BMI did not modify associations between other cardiometabolic factors and T.
Conclusions: Among men with diagnosed HG, endogenous T levels are strongly associated with body composition but not other cardiometabolic outcomes. Future analyses will be important to understand directionality of these associations and whether T therapy improves cardiometabolic outcomes in obese men with HG.
Disclosure: ABA: Consultant, Eli Lilly & Company, Principal Investigator, GlaxoSmithKline, Principal Investigator, Abbott Laboratories. MM: Consultant, Bayer, Inc., Consultant, Eli Lilly & Company. THJ: Consultant, Bayer Healthcare, Researcher, Bayer Healthcare, Speaker, Bayer Healthcare, Consultant, Eli Lilly & Company, Consultant, Pro Strakan, Researcher, Pro Strakan, Speaker, Pro Strakan, Consultant, Merck, Consultant, Clarus. RCR: Principal Investigator, Bayer Health Care, Consultant, Eli Lilly & Company, Consultant, Ferring Pharmaceuticals. Nothing to Disclose: JFM, GR, TMC
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters